JP2022525706A - アデノシン受容体アゴニスト - Google Patents

アデノシン受容体アゴニスト Download PDF

Info

Publication number
JP2022525706A
JP2022525706A JP2022504738A JP2022504738A JP2022525706A JP 2022525706 A JP2022525706 A JP 2022525706A JP 2022504738 A JP2022504738 A JP 2022504738A JP 2022504738 A JP2022504738 A JP 2022504738A JP 2022525706 A JP2022525706 A JP 2022525706A
Authority
JP
Japan
Prior art keywords
bnocpa
compound
adenosine
pain
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022504738A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020188288A5 (https=
JP2022525706A5 (https=
Inventor
フレングエッリ，ブルーノ
ウォール．マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Warwick
Original Assignee
University of Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Warwick filed Critical University of Warwick
Publication of JP2022525706A publication Critical patent/JP2022525706A/ja
Publication of JPWO2020188288A5 publication Critical patent/JPWO2020188288A5/ja
Publication of JP2022525706A5 publication Critical patent/JP2022525706A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2022504738A 2019-03-21 2020-03-19 アデノシン受容体アゴニスト Pending JP2022525706A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1903900.7A GB2582361A (en) 2019-03-21 2019-03-21 Adenosine receptor agonists
GB1903900.7 2019-03-21
PCT/GB2020/050734 WO2020188288A1 (en) 2019-03-21 2020-03-19 Adenosine receptor agonists

Publications (3)

Publication Number Publication Date
JP2022525706A true JP2022525706A (ja) 2022-05-18
JPWO2020188288A5 JPWO2020188288A5 (https=) 2023-03-27
JP2022525706A5 JP2022525706A5 (https=) 2023-03-27

Family

ID=66381433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022504738A Pending JP2022525706A (ja) 2019-03-21 2020-03-19 アデノシン受容体アゴニスト

Country Status (5)

Country Link
US (1) US20220152077A1 (https=)
EP (1) EP3941482A1 (https=)
JP (1) JP2022525706A (https=)
GB (1) GB2582361A (https=)
WO (1) WO2020188288A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113082020A (zh) * 2021-04-08 2021-07-09 徐州医科大学 一种腺苷受体激动剂的增强剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518042A (ja) * 1999-12-20 2003-06-03 グラクソ グループ リミテッド アデノシンａ１アゴニストの処方
JP2003518041A (ja) * 1999-12-20 2003-06-03 グラクソ グループ リミテッド アデノシンａ１アゴニストの処方
JP2003519104A (ja) * 1999-12-20 2003-06-17 グラクソ グループ リミテッド アデノシンａ１アゴニストの処方

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62692D0 (https=) * 1992-05-14 1992-05-14 Novo Nordisk As
CN103087133B (zh) * 2004-05-26 2016-09-14 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
WO2011011919A1 (zh) * 2009-07-31 2011-02-03 新道生技股份有限公司 一种降血糖的组合物
KR20130029049A (ko) * 2010-03-26 2013-03-21 이노텍 파마슈티컬스 코포레이션 아데노신 화합물 및 이의 용도
WO2017137528A1 (en) * 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518042A (ja) * 1999-12-20 2003-06-03 グラクソ グループ リミテッド アデノシンａ１アゴニストの処方
JP2003518041A (ja) * 1999-12-20 2003-06-03 グラクソ グループ リミテッド アデノシンａ１アゴニストの処方
JP2003519104A (ja) * 1999-12-20 2003-06-17 グラクソ グループ リミテッド アデノシンａ１アゴニストの処方

Also Published As

Publication number Publication date
EP3941482A1 (en) 2022-01-26
US20220152077A1 (en) 2022-05-19
GB2582361A (en) 2020-09-23
GB201903900D0 (en) 2019-05-08
WO2020188288A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
EP3307262B1 (en) Compounds for use in treating neuromuscular disorders
CN107531633A (zh) 5‑芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
HUE032948T2 (en) Opioid receptor ligands and methods of using and making same
CN102341380A (zh) 布美他尼、呋塞米、吡咯他尼、佐塞米和托拉塞米类似物、组合物和使用方法
MX2015003079A (es) Derivados de c17-alcanodiilo y alquenodiilo de acido oleanolico y metodos de uso de los mismos.
PL200551B1 (pl) Pochodne 3-(3-izopropylo-5-metylo-4H-1,2,4-triazol-4-ilo)-egzo-8-azabicyklo[3.2.1]oktanu, środek farmaceutyczny, zastosowanie tych pochodnych oraz środka farmaceutycznego i związki pośrednie
WO2018053373A1 (en) Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
EP2681209B1 (en) Compounds and methods for the treatment of pain and other disorders
TWI736519B (zh) 治療神經退化性疾病之組合物及方法
JP7472143B2 (ja) イオンチャネル阻害化合物を使用して過敏性咳またはかゆみを治療する方法
WO2016014847A1 (en) Ligands for alpha-7 nicotinic acetylcholine receptors and methods of treating neurological and inflammatory conditions
CN114712361A (zh) 用于预防或降低短暂性脑缺血发作发病率的组合物及方法
WO2022105665A1 (zh) 一种预防、治疗疼痛、炎症的化合物及其应用
TW201741316A (zh) 四氫異喹啉衍生物
JP2022525706A (ja) アデノシン受容体アゴニスト
Nagy et al. Synthesis and biological effects of some kynurenic acid analogs
CA2369746A1 (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
JP2023518309A (ja) 糖尿病性網膜症の治療において使用するためのソルチリン拮抗薬
EP4580618A2 (en) Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated
JP7366074B2 (ja) ３”，５”－ジアルコシベンゾイル－３’－アミノ－３’－デオキシアデノシン－５’－三リン酸及びその医薬用途
JP2008255118A (ja) 抗不整脈薬としてのプリンリボシド
EP3906927A1 (en) Use of dopamine d3 partial agonists for treating central nervous system disorders
JP2008517065A (ja) Ｂｒｃａ２−ｒａｄ５１相互作用の破壊のための組成物及び方法
JP2006513154A (ja) カリウムチャネルおよび／または皮質ニューロン活性モジュレーターとしての、ｎ−フェニルアントラニル酸および２−ベンズイミダゾロンの誘導体
US20240366571A1 (en) Modulators of sk4 potassium channel and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230316

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250708